Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Mar 21, 2017	Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 SOLANA BEACH, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company's abstract detailing compelling Phase 3 trial data for Gimoti™	View HTML Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 15.8 KB
Toggle Summary Mar 15, 2017	Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results SOLANA BEACH, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2016.	View HTML Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results 28.4 KB
Toggle Summary Mar 07, 2017	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results SOLANA BEACH, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the fourth quarter and full year ended December 31,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results 12 KB
Toggle Summary Mar 06, 2017	Evoke Pharma Announces Full Exercise of Underwriter's Option to Purchase Additional Shares SOLANA BEACH, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the underwriter of its previously announced public offering of approximately 2.4 million shares of	View HTML Evoke Pharma Announces Full Exercise of Underwriter's Option to Purchase Additional Shares 14.7 KB
Toggle Summary Feb 16, 2017	Evoke Pharma Announces Pricing of Public Offering of Common Stock SOLANA BEACH, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that it has priced an underwritten public offering of 2,413,793 shares of its common stock at a price to	View HTML Evoke Pharma Announces Pricing of Public Offering of Common Stock 15.2 KB
Toggle Summary Feb 15, 2017	Evoke Pharma Announces Proposed Public Offering of Common Stock SOLANA BEACH, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it intends to offer and sell shares of its common stock in a "firm commitment" underwritten	View HTML Evoke Pharma Announces Proposed Public Offering of Common Stock 15.4 KB
Toggle Summary Feb 15, 2017	FDA Exempts Evoke from Requirement for Human Factor Validation Study Company reaffirms NDA submission by year end 2017	View HTML FDA Exempts Evoke from Requirement for Human Factor Validation Study 194 KB
Toggle Summary Jan 09, 2017	Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference SOLANA BEACH, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, and its Chief Business Officer, Matt	View HTML Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference 14.7 KB
Toggle Summary Jan 04, 2017	Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity	View HTML Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial 25.5 KB
Toggle Summary Dec 15, 2016	Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data	View HTML Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti 16.2 KB